Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals

被引:22
作者
Hosono, O
Homma, T
Kobayashi, H
Munakata, Y
Nojima, Y
Iwamoto, A
Morimoto, C
机构
[1] Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo 1080071, Japan
[2] Univ Tokyo, Inst Med Sci, AIDS Res Ctr, Minato Ku, Tokyo 1080071, Japan
[3] Univ Tokyo, Inst Med Sci, Dept Infect Dis, Minato Ku, Tokyo 1080071, Japan
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
soluble CD26; dipeptidyl peptidase IV; HIV-RNA;
D O I
10.1006/clim.1999.4711
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human plasma contains soluble CD26/dipeptidyl peptidase IV (sCD26/DPPIV) although its physiological significance remains unclear. To determine whether the plasma sCD26 levels have clinical relevance in HIV-1 infected individuals, the concentration and DPPIV enzyme activity of plasma sCD26 were measured, While there is no significant difference between the plasma levels of sCD26 in 90 HIV-1 infected individuals and in 79 uninfected controls, specific DPPIV enzyme activity of sCD26 was significantly decreased in HIV-1 infected individuals (P < 0.0001). Specific DPPIV enzyme activity was correlated with the levels of CD4(+) T cells (r = 0.247; P < 0.02), CD8(+) T cells (r = 0.236; P < 0.03), and adenosine deaminase (r = 0.227; P < 0.05) and had an inverse correlation with HIV-1 RNA (Spearman's r = 0.474; P = 0.0012). Furthermore, recombinant sCD26 enhanced the in vitro PPD-induced response of lymphocytes from HIV-l infected individuals with decreased specific DPPIV enzyme activity. These results suggest that the specific DPPIV enzyme activity of plasma sCD26 may contribute to the immunopathogenesis of HIV infection. (C) 1999 Academic Press.
引用
收藏
页码:283 / 295
页数:13
相关论文
共 52 条
[31]  
MORIMOTO C, 1989, J IMMUNOL, V143, P3430
[32]   ELEVATED ADENOSINE-DEAMINASE AND PURINE NUCLEOSIDE PHOSPHORYLASE-ACTIVITY IN PERIPHERAL-BLOOD NULL LYMPHOCYTES FROM PATIENTS WITH ACQUIRED IMMUNE-DEFICIENCY SYNDROME [J].
MURRAY, JL ;
LOFTIN, KC ;
MUNN, CG ;
REUBEN, JM ;
MANSELL, PWA ;
HERSH, EM .
BLOOD, 1985, 65 (06) :1318-1324
[33]  
NILIUS R, 1991, PHYSIOL RES, V40, P95
[34]   Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV [J].
Ohtsuki, T ;
Hosono, O ;
Kobayashi, H ;
Munakata, Y ;
Souta, A ;
Shioda, T ;
Morimoto, C .
FEBS LETTERS, 1998, 431 (02) :236-240
[35]   Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage [J].
Oravecz, T ;
Pall, M ;
Roderiquez, G ;
Gorrell, MD ;
Ditto, M ;
Nguyen, NY ;
Boykins, R ;
Unsworth, E ;
Norcross, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (11) :1865-1872
[36]   Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α [J].
Proost, P ;
Struyf, S ;
Schols, D ;
Durinx, C ;
Wuyts, A ;
Lenaerts, JP ;
De Clercq, E ;
De Meester, I ;
Van Damme, J .
FEBS LETTERS, 1998, 432 (1-2) :73-76
[37]   Amino-terminal truncation of chemokines by CD26/dipeptidylpeptidase IV - Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection [J].
Proost, P ;
De Meester, I ;
Schols, D ;
Struyf, S ;
Lambeir, AM ;
Wuyts, A ;
Opdenakker, G ;
De Clercq, E ;
Scharpe, S ;
Van Damme, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (13) :7222-7227
[38]   HIV viral load markers in clinical practice [J].
Saag, MS ;
Holodniy, M ;
Kuritzkes, DR ;
OBrien, WA ;
Coombs, R ;
Poscher, ME ;
Jacobsen, DM ;
Shaw, GM ;
Richman, DD ;
Volberding, PA .
NATURE MEDICINE, 1996, 2 (06) :625-629
[39]  
SCHARPE S, 1988, CLIN CHEM, V34, P2299
[40]   Potentiation of the immune response in HIV-1(+) individuals [J].
Schmitz, T ;
Underwood, R ;
Khiroya, R ;
Bachovchin, WW ;
Huber, BT .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (06) :1545-1549